A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer; Non Small Cell Lung Cancer Interventions: Drug: LMB-100; Drug: pembrolizumab; Diagnostic Test: Mesothelin Expression Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials